Description
The aim of this reprint is to immerse the reader in the transformative advancements in drug-based therapies for cardiovascular diseases and diabetes, two major contributors to global morbidity and mortality. From the groundbreaking use of sodium-glucose cotransporter 2 inhibitors in heart failure and diabetes management to the development of novel incretin therapies and innovative insulin delivery systems, this collection examines the potential and promise of these cutting-edge pharmacological strategies. In this special issue, leading experts in the fields of cardiology and diabetology share their insights, clinical findings, and visions for the future of integrated therapeutic approaches. Together, we embark on a journey to redefine the prevention and treatment of cardiovascular and metabolic disorders, offering sustainable solutions to improve patient outcomes and quality of life. This Special Issue paves the way towards a healthier, more resilient future where the burden of these interconnected conditions is mitigated by science-driven innovations.
